PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
19 hedge funds and large institutions have $65.8M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
210% more capital invested
Capital invested by funds: $21.2M → $65.8M (+$44.6M)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
27% more funds holding
Funds holding: 15 → 19 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.21M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$374K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$302K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$249K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.02M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$592K |
| 3 |
Citigroup
New York
|
-$351K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$167K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$109K |
PHAS Hedge Fund Activity: Q1 2019 in Review
19 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q1 2019, worth a combined $65.8M — up 210% from $21.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PHAS positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $1.21M. The largest seller was Cormorant Asset Management, cutting an estimated $1.02M.
- 19 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q1 2019, up from 15 in Q4 2018.
- Funds reported $65.8M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 210% quarter-over-quarter.
- 9 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 5 closed out, a net change of +4 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was Rock Springs Capital Management, an estimated $1.21M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Cormorant Asset Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2019.